A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Active, not recruiting · Phase 1, Phase 2 · NCT06305247
Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Solid Tumor
At a glance
- Research payments reported, 2025
- $783,162
- U.S. investigators named
- 10
- Sites paid
- 13
- Planned or actual enrollment
- 36
About the trial
- Sponsor
- Ipsen
- Tested
- IPN01194 (drug), IPN01194 (drug)
- Dates
- Started 2024-04-03; completion 2028-03-20
- Results posted
- Not yet
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. 'Advanced solid tumours' refers to cancers that can occur in several places, including cancers in organs or tissues that have spread from their original site to nearby tissues or other parts of the body. In this study, all participants will receive the study drug, which will be taken by mouth (orally).
From ClinicalTrials.gov, last updated 2026-09-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ipsen Pharma Sas reported $783,162 in research payments for this study in 2025 (292 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Omid Hamid, M.D. Hematology & Oncology · Santa Monica, CA
- Michael Cecchini, MD Hematology & Oncology · New Haven, CT
- Manish Sharma, M.D. Medical Oncology · Grand Rapids, MI
- Meredith A. Mckean, M.D. Hematology & Oncology · Nashville, TN
- Meredith S. Pelster, M.D. Hematology & Oncology · Nashville, TN
- Minal A. Barve, M.D. Medical Oncology · Dallas, TX
- Shumei Kato, M.B. Internal Medicine · Houston, TX
- Douglas W. Orr, MD Medical Oncology · Dallas, TX
- William B. Mckean JR., M.D., PH.D. Student in an Organized Health Care Education/Training Program · Salt Lake City, UT
- Alexander I. Spira, M.D. Medical Oncology · Fairfax, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Sarah Cannon Research Institute $192,816
- Cedars Sinai Internal Medicine Encino $126,930
- Yale Univ $102,534
- Cedars Sinai the Angeles Clinic and Research Institute $97,108
- Next Oncology $86,106
- Yale University School of Medicine $55,716
- Cancer and Hematology Centers of Western Michigan, PC $51,730
- Granger Medical Clinic $46,154
- University of California San Diego Jacobs Medical Center $15,253
- Yale Cancer Center $3,512
- Scri Oncology PArtners $3,245
- Exceptional Care Medical Group $1,887
- Mary Crowley Cancer Research $172
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.